ProCE Banner Activity

Phase II Study: Luspatercept for Treatment of Myelofibrosis-Associated Anemia

Slideset Download
Conference Coverage
Initial results from ongoing phase II study suggest clinical activity of luspatercept in patients with MF-associated anemia.

Released: December 08, 2019

Expiration: December 06, 2020

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Celgene

Dova Pharmaceuticals

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Karyopharm Therapeutics

Loxo Oncology subsidiary of Eli Lilly

Pharmacyclics an AbbVie Company